

*CLAIM AMENDMENTS*

Please amend the claims as follows:

1. (Currently Amended) A composition comprising a cationic liposome ~~containing~~ comprising a cationic lipid, phosphatidylcholine and cholesterol.
2. (Currently Amended) A composition of claim 1 wherein the liposome contains an antisense oligonucleotide ~~sequence~~.
3. (Currently Amended) A composition of claim 2 wherein the antisense oligonucleotide ~~sequence~~ is a raf antisense oligodeoxynucleotide.
4. (Currently Amended) A composition of claim 3 wherein the antisense oligonucleotide comprises a sequence ~~is~~ of the formula 5' -GTGCTCCATTGATGC- 3' (SEQ ID NO: 1) wherein only the terminal sequences are phosphorothioated.
5. (Original) A composition of claim 1 in a pharmaceutically acceptable carrier.
6. (Original) A composition of claim 4 in a pharmaceutically acceptable carrier.
7. (Currently Amended) A composition of claim ~~[[1]]~~ 5 wherein the pharmaceutically acceptable carrier is isotonic.
8. (Currently Amended) A composition of claim ~~[[4]]~~ 7 wherein the pharmaceutically acceptable carrier is buffered, isotonic solution.
9. (Currently Amended) A method of radiosensitizing tumor tissue by administration of a radiosensitizing effective amount of at least one antisense oligonucleotide of no more than 40 bases containing the sequence 5' -GTGCTCCATTGATGC- 3' (SEQ ID NO: 1), wherein said oligonucleodide is contained within a liposome comprising a non-toxic cationic lipid.
10. (Original) A method of claim 9 wherein the oligonucleotide is phosphorothioated at only the end nucleotides.
11. (Canceled)

12. (Original) A method of claim 9 wherein the oligonucleotide is administered intravenously.

13. (Original) A method of claim 9 wherein the oligonucleotide is administered directly to the target tissue.

14. (Original) A method of claim 9 wherein the oligonucleotide is administered into the arterial supply to the target tissue.

15. (Previously Presented) A method of claim 9 wherein the oligonucleotide is of the formula 5' -GTGCTCCATTGATGC- 3' (SEQ ID NO: 1) and only the end bases are phosphorothioated.

16. (Currently Amended) A composition of matter comprising liposomes containing oligonucleotides comprising the sequence 5' -GTGCTCCATTGATGC- 3' (SEQ ID NO: 1) in a pharmaceutically acceptable carrier.

17. (Original) A composition of claim 1 wherein the cationic lipid is dimethyldioctadecyl ammonium bromide.

18. (Previously Presented) An improved method of treating a patient having cancerous tumor tissue comprising the administration of therapeutic radiation wherein the improvement comprises sensitizing said cancerous tumor tissue by the administration of radiosensitizing composition comprising a cationic liposome, phosphatidylcholine and cholesterol which cationic liposome has encapsulated therein an antisense oligonucleotide of no more than 40 bases that specifically binds to an oncogene nucleic acid sequence expressed by said tumor tissue.

19. (Previously Presented) The method of claim 18, wherein the oncogene is selected from the group consisting of ras, raf, cot, mos and myc.

20. (Previously Presented) The method of claim 19, wherein the oncogene is raf-1.

21. (Previously Presented) The method of claim 18, wherein said tumor tissue is a solid tumor.

22. (Previously Presented) The method of claim 18, wherein said tumor is a laryngeal squamous carcinoma.

23. (Previously Presented) The method of claim 18, wherein radiation and said cationic liposomes are administered together.

24. (Previously Presented) The method of claim 18, wherein said radiation and cationic liposomes are administered separately.

25. (Previously Presented) The method of claim 24, wherein said cationic liposome is administered prior to radiation.

26. (Previously Presented) A method of claim 18 wherein the oligonucleotide is administered directly to the target tissue.

27. (Previously Presented) A method of claim 18 wherein the oligonucleotide is administered into the arterial supply to the target tissue.

28. (New) A composition of claim 3 wherein the antisense oligonucleotide comprises a sequence of the formula 5' –GTGCTCCATTGATGC- 3' (SEQ ID NO: 1).

29. (New) A composition of claim 28 in a pharmaceutically acceptable carrier.

30. (New) A composition of claim 29, wherein the pharmaceutically acceptable carrier is isotonic.

31. (New) A composition of claim 30, wherein the pharmaceutically acceptable carrier is buffered, isotonic solution.

32. (New) A composition of claim 3 wherein the antisense oligonucleotide comprises a sequence of the formula 5' – CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2) wherein only the terminal sequences are phosphorothioated.

33. (New) A composition of claim 32 in a pharmaceutically acceptable carrier.

34. (New) A composition of claim 33, wherein the pharmaceutically acceptable carrier is isotonic.

35. (New) A composition of claim 34, wherein the pharmaceutically acceptable carrier is buffered, isotonic solution.

36. (New) A composition of claim 3 wherein the antisense oligonucleotide comprises a sequence of the formula 5' – CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2).

37. (New) A composition of claim 36 in a pharmaceutically acceptable carrier.

38. (New) A composition of claim 37, wherein the pharmaceutically acceptable carrier is isotonic.

39. (New) A composition of claim 38, wherein the pharmaceutically acceptable carrier is buffered, isotonic solution.

40. (New) A composition of claim 6, wherein the pharmaceutically acceptable carrier is isotonic.

41. (New) A composition of claim 40, wherein the pharmaceutically acceptable carrier is buffered, isotonic solution.

42. (New) A method of claim 9 wherein the oligonucleotide is of the formula 5' - GTGCTCCATTGATGC- 3' (SEQ ID NO: 1).

43. (New) A method of claim 9 wherein the oligonucleotide is of the formula 5' – CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2) and only the end bases are phosphorothioated.

44. (New) A method of claim 9 wherein the oligonucleotide is of the formula 5' – CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2).

45. (New) A composition of matter comprising liposomes containing oligonucleotides comprising the sequence 5' – CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2) in a pharmaceutically acceptable carrier.

46. (New) An oligonucleotide of no more than 40 bases comprising the sequence 5' -GTGCTCCATTGATGC- 3' (SEQ ID NO: 1).

47. (New) An oligonucleotide according to claim 46, wherein the end bases are phosphorothioated.

48. (New) An oligonucleotide according to claim 47, wherein only the end bases are phosphorothioated.

49. (New) An oligonucleotide according to claim 46, having the sequence 5' - GTGCTCCATTGATGC- 3' (SEQ ID NO: 1).

50. (New) An oligonucleotide according to claim 47, having the sequence 5' - GTGCTCCATTGATGC- 3' (SEQ ID NO: 1).

51. (New) An oligonucleotide according to claim 48, having the sequence 5' - GTGCTCCATTGATGC- 3' (SEQ ID NO: 1).

52. (New) An oligonucleotide according to claim 46, having the sequence 5' - CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2).

53. (New) An oligonucleotide according to claim 47, having the sequence 5' - CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2).

54. (New) An oligonucleotide according to claim 48, having the sequence 5' - CCTGTATGTGCTCCATTGATGCAGC- 3' (SEQ ID NO: 2).